You are here:
NICE
NICE Guidance
Conditions and diseases
Blood and immune system conditions
Blood and bone marrow cancers
Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia
Technology appraisal guidance
Reference number:
TA119
Published:
28 February 2007
Guidance
Tools and resources
Information for the public
Evidence
History
Download guidance (PDF)
Overview
1 Guidance
2 The technology
3 The manufacturer's submission
4 Consideration of the evidence
5 Implementation
6 Recommendations for further research
7 Related NICE guidance
8 Review of guidance
Appendix A. Appraisal Committee members and NICE project team
Appendix B. Sources of evidence considered by the Committee
Appendix C. List of organisations involved in this appraisal
Changes after publication
About this guidance
Changes after publication
March 2014:
minor maintenance
March 2012:
minor maintenance
Next page
About this guidance
Previous page
Appendix C. List of organisations involved in this appraisal